Maspin reintroduction was found to reverse epithelial-to-mesenchymal transition of prostate cancer cells by inhibiting HDAC1 activity and suppressing TGF-β/β-catenin /E-cadherin pathway [48, 49]. This evidence concerns the gene CDH1 and prostate carcinoma.